Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer

Pancreas

Volumn 19, Issue 4, 1999, Pages 370-376

  Wagner, Markus ^a   Kleeff, Jörg ^a   Friess, Helmut ^b   Büchler, Markus W ^b   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

MMP9; PAI 1; Pancreatic cancer; TGF receptor type II

Indexed keywords

GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 0032711157     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199911000-00008     Document Type: Article

References (48)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. Cancer 1997:47:5-27.
3. Bramhall SR, Neoptolemos JP. Adjuvant chemotherapy in pancreatic cancer. Int J Pancreatol 1997;21:59-63.
4. Abrams RA. Role of radiation therapy in the management of the patient with pancreatic cancer. Oncology 1996;10:13-7.
5. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-60.
6. Korc M. Growth factors in pancreatic cancer. In: Dervenis CG, ed. Advances in pancreatic disease. New York: Georg Thieme Verlag, 1996:34-41.
7. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
8. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597-641.
9. Wrana JL, Attisano L, Wiser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-7.
10. Heldin C-H, Miyazono K, tenDijke K. TGF-β signalling from cell membrane to nucleus trough SMAD proteins. Nature 1997;390: 465-71.
11. Liu F, Pouponnot C, Massague J. Dual role of the SMAD4/DPC4 tumor suppressor in TGF-β-inducible transcriptional complexes. Genes Dev 1997;11:3157-67.
12. Grondahl Hansen J, Hilsenbeck SG, Christensen U, Clark GM, Osborne CK, Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:153-631.
13. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator: its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78: 487-92.
14. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
15. Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997;76:306-11.
16. Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol 1996; 23:316-24.
17. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/ inflammatory aspect. Jpn J Cancer Res 1997;88:72-81.
18. Wagner SN, Atkinson MJ, Thanner S, et al. Type-1 plasminogen activator inhibitor in human renal cell carcinoma. J Pathol 1996; 179:95-9.
19. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
20. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
21. Lu Z, Friess H, Graber HU, et al. Presence of two signaling TGF-β receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.
22. Kleeff J, Korc M. Up-regulation of transforming growth factor-β receptors by TGF-β1 in COLO-357 cells. J Biol Chem 1998;273: 7495-500.
23. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8.
24. Kornmann M, Link KH, Lenz H-J, et al. Thymidilate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;118:29-35.
25. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-52.
26. Steiner MS, Barrack ER. Transforming growth factor-β overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
27. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
28. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-9.
29. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, Korc M. Smad6 suppresses TGF-β induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999;255:268-73.
30. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67.
31. Rha SY, Kim JH, Roh JK, et al. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat 1997;43:175-81.
32. Sier CF, Kubben FJ, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74: 413-7.
33. Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 1993;88:1928-33.
34. Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-50.
35. Koshiba T, Hosotani R, Wada M, et al. Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today 1997;27:302-4.
36. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 1993;260:1335-8.
37. Saitoh M, Nishitoh H, Amagasa T, Miyazono K, Takagi M, Ichijo H. Identification of important regions in the cytoplasmic juxta-membrane domain of type I receptor that separate signaling pathways of transforming growth factor-beta. J Biol Chem 1996;271: 2769-75.
38. Yamamoto H, Ueno H, Ooshima A, Takeshati A. Adenovirus-mediated transfer of a truncated transforming growth factor-β (TGF-β) type II receptor completely and specifically abolishes diverse signaling by TGF-β in vascular wall cells in primary culture. J Biol Chem 1996;271:16253-9.
39. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-4.
40. Maesawa C, Tamura G, Nishizuka S, et al. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res 1997;88:340-3.
41. Powell SM, Harper JC, Hamilton SR, Robinson CR, Cummings OW. Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997;57:4221-4.
42. DeCoteau JF, Knaus PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997;94:5877-81.
43. Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 1996;56:44-8.
44. Wang J, Han W, Zborowska E, et al. Reduced expression of transforming growth factor-β type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996;271: 17366-71.
45. Markowitz S, Wang J, Meyerhoff L, et al. Inactivation of the TGF-β type II receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
46. Chung YJ, Song JM, Lee JY, et al. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. Cancer Res 1996;56:4662-5.
47. Izumoto S, Arita N, Ohnishi T, et al. Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett 1997;112:251-6.
48. Vincent F, Hagiwara K, Ke Y, et al. Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun 1996;223:561-4.